


12/05/01



J1044 U.S. PTO

12-10-01

PTO/SB/05 (3-01)

Approved for use through 09/30/2000. OMB 0651-0032

Please type a plus sign (+) inside this box → ☐

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

Attorney Docket No.

PC9983A

First Inventor

Yasuhiro Katsu

Title

N-Benzenesulfonyl L-Proline Compounds As
Bradykinin Antagonists

Express Mail Label No.

EL 874867470

(Only for new nonapplications under 37 C.F.R. §1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. ☐ Applicant claims small entity status
See 37 CFR 1.27

3. ☒ Specification [Total Pages (preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

4. ☐ Drawing(s) (35 U.S.C. 113) [Total sheets

5. ☐ Oath or Declaration [Total pages

a. ☐ Newly executed (original or copy)

b. ☐ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 18 completed)

i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).

6. ☒ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or
computer Program (Appendix)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer Readable Copy (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies)
- ii. ☐ Paper
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35
or its equivalent.
17. ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37CFR 1.76.

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information:

Examiner

Group/Art Unit:

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under
Box 5b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below



23913

Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	

NAME (Print/Type)	Elsa Djuardi	Registration No. (Attorney/Agent)	45,963
Signature	<i>Elsa Djuardi</i>	Date	12/5/01

FEE TRANSMITTAL For FY 2001

Patent Fees are subject to annual Revision

Complete if Known

Application Number	Unassigned
Filing Date	Concurrent herewith
First Named Inventor	Yasuhiro Katsu
Examiner Name	Unassigned
Group/Art Unit	Unassigned
Attorney Docket No.	PC9983A

Total Amount of Payment (\$)740

METHOD OF PAYMENT

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to

Deposit Account Number 16-1445

Deposit Account Name Pfizer Inc

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status.

See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	355	Utility filing fee	740
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	filing fee	
SUBTOTAL (1) (\$)					740

2. EXTRA CLAIM FEES

Large Entity		Small Entity		Extra Claims	Fee from below	Fee Paid
Fee Code	Fee Code	Fee Code	Fee Code			
10	-20**=	0	X	0	=	0
Independent Claims	1	-3**=	0	X	0	= 0
Multiple Dependent					=	0

Large Entity Fee Code	Large Entity Fee Code	Small Entity Fee Code	Small Entity Fee Code	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	80	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)				(\$) 0

** or number previously paid, if greater, For Reissues, see above

3. ADDITIONAL FEES

Fee Code	Large Entity Fee (\$)	Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55		
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55		
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	Request for Continued Examination(RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other (specify)					
*Reduced by Basic Filing Fee Paid					
Subtotal (3)					

SUBMITTED BY

Complete (if applicable)

Type or Printed Name	Elsa Djuardi	Registration No. (Attorney/Agent)	45,963	Telephone	212-733-3678
Signature	[Signature]			Date	12/05/01

CERTIFICATE OF MAILING - EXPRESS MAIL

PFIZER DOCKET NO: PC9983A

APPLICATION NUMBER: N/A

TITLE: : N-BENZENESULFONYL L-PROLINE COMPOUNDS
AS BRADYKININ ANTAGONISTS

APPLICANT: Y. Katsu *et al*


"Express Mail" mailing label number EL874867470 US

Date of Deposit December 5, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box Patent Application, Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Michelle Dungee

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

Pfizer, Inc
Patent Department
235 East 42nd Street
New York, NY 10017-5755